Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection (CAMERA2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02365493|
Recruitment Status : Terminated (Recommendation of the Data Safety Monitoring Committee)
First Posted : February 19, 2015
Last Update Posted : December 19, 2018
The aim of this clinical trial is to determine whether a novel combination antibiotic treatment (vancomycin/daptomycin + beta-lactam) is superior to the standard antibiotic treatment (vancomycin/daptomycin) for hospitalised adults with Methicillin Resistant Staphylococcus aureus bacteraemia. The hypothesis is that the addition of beta-lactam antibiotics (these are antibiotics from the penicillin family) to the standard therapy will lead to more efficient bacterial killing and hence lead to faster clearance of bacteria from the blood stream and other areas of infection, thereby reducing the risk of the spread of infection and death.
The study design is an investigator-initiated, multi-centre, open-label, randomised controlled trial. This will include 440 participants diagnosed with Methicillin Resistant Staphylococcus aureus bacteraemia recruited over a period of 4 years (July 2015 - June 2019) from within Infectious Diseases inpatient units across 21 hospital sites including 18 from within Australia and 3 located in Singapore. Participation will be voluntary and subject to informed consent. The participants will be randomised 1:1 to either the standard therapy group or combination therapy group. The combination therapy will include a treatment of intravenous beta-lactam for the first 7 days of treatment, in addition to the standard treatment (either vancomycin or daptomycin). The primary outcome measure will be complication-free survival 90 days post randomisation.
|Condition or disease||Intervention/treatment||Phase|
|Methicillin-Resistant Staphylococcus Aureus||Drug: Beta-Lactam||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||358 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||CAMERA 2 - Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection - An Investigator-initiated, Multi-centre, Parallel Group, Open Labelled Randomised Controlled Trial|
|Actual Study Start Date :||August 26, 2015|
|Actual Primary Completion Date :||October 24, 2018|
|Actual Study Completion Date :||October 24, 2018|
No Intervention: Standard therapy
Intravenous vancomycin dosed as per Australian Therapeutic Guidelines (loading dose of 25 mg/kg followed by maintenance dose of 15-20 mg/kg every 12 hours) with subsequent adjustment to maintain trough levels at 15-20 mg/dL OR Intravenous daptomycin 6-10 mg/kg per day, adjusted for renal function (details of renally adjusted dosing provided in full protocol).
The choice of daptomycin or vancomycin is clinician-determined and may be influenced by such factors as local practice, the vancomycin minimum inhibitory concentration (MIC) of the isolate and evidence emerging during the course of the study
Experimental: Standard therapy + Beta-Lactam
In addition to standard treatment an intravenous Beta-Lactam (β-lactam) will be added for the first 7 calendar days following randomisation (randomisation is day 1 - hence patients will receive 6-7 days of β-lactam). This β-lactam will be intravenous flucloxacillin 2g every 6 hours in Australia and intravenous cloxacillin 2g every 6 hours in Singapore. For those with a history of minor allergy to any penicillin (rash or unclear history, but not anaphylaxis or angiooedema), it will be intravenous cefazolin 2g every 8 hours. For haemodialysis patients, it will usually be cefazolin 2g three times per week post dialysis, however clinicians are also free to choose intermittent (flu)cloxacillin, dosed as for glomerular filtration rate (GFR ) <10, if they desire.
- Complication-free 90 day survival [ Time Frame: Time period from randomisation (day 1) to day 90 ]
Composite outcome at 90 days - any of:
- All-cause mortality
- Persistent bacteraemia at day 5 or beyond
- Microbiological relapse - positive blood culture for MRSA at least 72 hours after a preceding negative culture
- Microbiological treatment failure. Positive sterile site culture for MRSA at least 14 days after randomisation.
- All-cause mortality at days 14, 42 and 90 days [ Time Frame: Time period from randomisation (day 1) to day 90 ]
- Persistent bacteraemia at day 2 [ Time Frame: Time period from randomisation (day 1) to day 90 ]
- Persistent bacteraemia at day 5 or beyond [ Time Frame: Time period from randomisation (day 1) to day 90 ]
- Acute kidney injury defined as ≥ stage 1 modified RIFLE criteria at any time within the first 7 days, OR new need for renal replacement therapy at any time from days 1 to 90. Excludes participants already on haemodialysis. [ Time Frame: Time period from randomisation (day 1) to day 90 ]>=stage 1 modified RIFLE criteria (1.5-fold increase in the serum creatinine, or glomerular filtration rate (GFR) decrease by 25 percent). This endpoint does not apply to participants who were already on haemodialysis at randomisation.
- Microbiological relapse - positive blood culture for MRSA at least 72 hours after a preceding negative culture [ Time Frame: Time period from randomisation (day 1) to day 90 ]
- Microbiological treatment failure. Positive sterile site culture for MRSA at least 14 days after randomisation [ Time Frame: Time period from randomisation (day 1) to day 90 ]
- Duration of intravenous antibiotic treatment [ Time Frame: Time period from randomisation (day 1) to day 90 ]
- Direct health care costs [ Time Frame: Time period from randomisation (day 1) to day 90 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02365493
|Principal Investigator:||Joshua Davis, MBBS, FRACP||Menzies School of Health Research|
|Principal Investigator:||Steven Tong, MBBS, FRACP||Menzies School of Health Research|